OX40: Targeted immunotherapy - Implications for tempering autoimmunity and enhancing vaccines

Trends in Immunology

Volumn 23, Issue 2, 2002, Pages 102-109

  Weinberg, Andrew D ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CYTOKINE; LIGAND; PROTEIN OX40; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CELL ACTIVATION; CELL COUNT; CELL FUNCTION; CELL ISOLATION; CELL SPECIFICITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE MODEL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; INFLAMMATION; MEMORY CELL; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD27; AUTOIMMUNITY; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; OX40 LIGAND; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; VACCINES;

EID: 0036476664     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(01)02127-5     Document Type: Review

References (40)

1. + spinal-cord T cells of Lewis rats with EAE
2. + T blasts
3. + T lymphocytes - A molecule related to nerve growth factor receptor
4. Molecular characterization of murine and human OX40/OX40-ligand systems: Identification of a human OX40 ligand as the HTLV-1-regulated protein gp34
5. OX40 ligand: A potent costimulatory molecule for sustaining primary CD4 T-cell responses
6. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis
7. Expression of the T-cell activation antigen, OX40, identifies alloreactive T cells in acute graft-versus-host disease
8. Target-organ-specific up-regulation of the MRC OX40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis
9. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis
10. + T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis
11. Analysis of T-cell receptor β-chains in Lewis rats with experimental allergic encephalomyelitis: Conserved complementarity-determining region 3
12. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. II. Biased T-cell receptor Vβ expression predominates in spinal-cord-infiltrating T cells
13. Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis
14. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells
15. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells
16. Blocking OX40/OX40-ligand interaction in vitro and in vivo leads to decreased T-cell function and amelioration of experimental allergic encephalomyelitis
17. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40-ligand monoclonal antibody: A critical role for OX40 ligand in migration, but not development, of pathogenic T cells
18. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T-cell-restored SCID mice
19. Regulation of T-cell activation in vitro and in vivo by targeting the OX40-OX40-ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40-ligand-IgG fusion protein
20. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease
21. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone-marrow transplantation
22. Contribution of OX40/OX40-ligand interaction to the pathogenesis of rheumatoid arthritis
23. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40
24. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis)
25. Presence of the T-cell activation marker OX40 on tumor-infiltrating lymphocytes and draining lymph-node cells from patients with melanoma and head and neck cancers
26. OX40 (CD134)
27. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma
28. Strong and selective glomerular localization of CD134 ligand and TNF receptor 1 in proliferative lupus nephritis
29. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX40
30. Engagement of the OX40 receptor in vivo enhances antitumor immunity
31. CD4 T-cell traffic control: In vivo evidence that ligation of OX40 on CD4 T cells by OX40 ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles
32. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC-chemokine-receptor-5-positive CD4 cells and germinal centers
33. Danger and OX40-receptor signaling synergize to enhance memory T-cell survival by inhibiting peripheral deletion
34. L and Bcl-2 expression and is essential for long-term survival of CD4 T cells
35. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion
36. OX40-deficient mice are defective in Th-cell proliferation but are competent in generating B-cell and CTL responses after virus infection
37. Impairment of antigen-presenting-cell function in mice lacking expression of OX40 ligand
38. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance
39. Therapeutic efficacy of OX40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth
40. Augmentation vs. inhibition: Effects of conjunctional OX40R mAb and IL-2 treatment on adoptive immunotherapy of advanced tumor